MRSN - Mersana Therapeutics, Inc.
IEX Last Trade
1.62
-0.510 -31.481%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:11:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$2.13
-0.51
-23.94%
Fundamental analysis
25%
Profitability
25%
Dept financing
19%
Liquidity
65%
Performance
15%
Performance
5 Days
1.25%
1 Month
-19.00%
3 Months
-10.00%
6 Months
-22.86%
1 Year
-19.80%
2 Year
-71.63%
Key data
Stock price
$1.62
DAY RANGE
$1.47 - $2.13
52 WEEK RANGE
$1.36 - $6.28
52 WEEK CHANGE
-$28.95
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Anna Protopapas
Region: US
Website: mersana.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: mersana.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Mersana Therapeutics, Inc. develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for ovarian cancer and NSCLC adenocarcinoma.
Recent news